文献速递创伤与烧伤重症综合管理与镇静镇痛

高维蛋白质组学识别与人类创伤结局相关的器官损伤模式

High-dimensional proteomics identifies organ injury patterns associated with outcomes in human trauma.
PubMed 文献 · J Trauma Acute Care Surg · 2023-02-13
一句话结论严重创伤后72小时持续升高的心脏、肝、神经和肺损伤标志物与不良结局相关,心脏损伤标志物升高最显著并与炎症及内皮损伤标志物正相关。

该研究对两项院前随机试验中纳入的142例创伤患者(非缓解组78例、缓解组34例、低ISS对照组30例)在到达创伤中心后0、24、72小时采集血浆,进行多重蛋白质组学检测,并通过文献综述和人类蛋白质图谱交叉引用确定组织特异性生物标志物。结果发现入院时即出现广泛的组织特异性损伤标志物释放,非缓解组更为明显;至72小时,非缓解组仍有9种心脏、3种肝脏、8种神经和3种肺蛋白显著高于缓解组。心脏损伤标志物在72小时升高最显著,且与促炎介质和内皮损伤标志物呈显著正相关;非缓解组脂肪酸代谢物(尤其是酰基肉碱和胆碱)浓度低于缓解组。作者认为非缓解组持续的心肌损伤可能由代谢应激、炎症和内皮病变等多种因素共同导致。

要点

  • 严重创伤患者入院时即出现广泛组织特异性损伤标志物释放,非缓解组(死亡>72小时或需≥7天重症监护)释放程度高于缓解组。
  • 至72小时,非缓解组仍有9种心脏、3种肝脏、8种神经和3种肺蛋白显著高于缓解组(p<0.1)。
  • 心脏损伤标志物在72小时非缓解组中升高最显著,并与促炎介质及内皮损伤标志物呈显著正相关。
  • 非缓解组脂肪酸代谢物(尤其是酰基肉碱和胆碱)浓度低于缓解组。
  • 非缓解组中位ISS为30,缓解组为22,低ISS对照组为1。

适用人群与场景

  • 来自两项院前随机试验的创伤患者,在到达创伤中心后0、24、72小时采集血浆。
  • 按结局分为非缓解组(死亡>72小时或需≥7天重症监护,78例,中位ISS 30)、缓解组(存活至30天且需<7天重症监护,34例,中位ISS 22)和低ISS对照组(30例,中位ISS 1)。

研究设计与关键结果

  • 研究类型为对两项院前随机试验中纳入的创伤患者血浆样本进行多重蛋白质组学(SomaLogic Inc., Boulder, CO)和未靶向血浆代谢组学(Metabolon Inc., Durham, NC)分析,共142例。
  • 入院时观察到广泛的组织特异性损伤标志物释放,非缓解组高于缓解组。
  • 至72小时,非缓解组与缓解组相比,仍有9种心脏、3种肝脏、8种神经和3种肺蛋白显著升高(p<0.1)。
  • 心脏损伤标志物在72小时非缓解组中升高最显著,并与促炎介质和内皮损伤标志物呈显著正相关。
  • 非缓解组脂肪酸代谢物浓度低于缓解组,尤其是酰基肉碱和胆碱。

证据类型、等级与局限

  • 证据类型:对两项院前随机试验中纳入患者血浆样本的蛋白质组学和代谢组学分析。
  • 显著性阈值:p<0.1(经错误发现率校正)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,严重创伤后复杂临床病程患者的肝脏、肺、神经尤其是心脏损伤标志物持续升高,非缓解组持续的心肌损伤可能由代谢应激、炎症和内皮病变等多种因素共同导致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Severe traumatic injury with shock can lead to direct and indirect organ injury; however, tissue-specific biomarkers are limited in clinical panels. We used proteomic and metabolomic databases to identify organ injury patterns after severe injury in humans.

METHODS: Plasma samples (times 0, 24, and 72 hours after arrival to trauma center) from injured patients enrolled in two randomized prehospital trials were subjected to multiplexed proteomics (SomaLogic Inc., Boulder, CO). Patients were categorized by outcome: nonresolvers (died >72 hours or required ≥7 days of critical care), resolvers (survived to 30 days and required <7 days of critical care), and low Injury Severity Score (ISS) controls. Established tissue-specific biomarkers were identified through a literature review and cross-referenced with tissue specificity from the Human Protein Atlas. Untargeted plasma metabolomics (Metabolon Inc., Durham, NC), inflammatory mediators, and endothelial damage markers were correlated with injury biomarkers. Kruskal-Wallis/Mann-Whitney U tests with false discovery rate correction assessed differences in biomarker expression across outcome groups (significance; p < 0.1).

RESULTS: Of 142 patients, 78 were nonresolvers (median ISS, 30), 34 were resolvers (median ISS, 22), and 30 were low ISS controls (median ISS, 1). A broad release of tissue-specific damage markers was observed at admission; this was greater in nonresolvers. By 72 hours, nine cardiac, three liver, eight neurologic, and three pulmonary proteins remained significantly elevated in nonresolvers compared with resolvers. Cardiac damage biomarkers showed the greatest elevations at 72 hours in nonresolvers and had significant positive correlations with proinflammatory mediators and endothelial damage markers. Nonresolvers had lower concentrations of fatty acid metabolites compared with resolvers, particularly acyl carnitines and cholines.

CONCLUSION: We identified an immediate release of tissue-specific biomarkers with sustained elevation in the liver, pulmonary, neurologic, and especially cardiac injury biomarkers in patients with complex clinical courses after severe injury. The persistent myocardial injury in nonresolvers may be due to a combination of factors including metabolic stress, inflammation, and endotheliopathy.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Li SR, Moheimani H, Herzig B, et al. High-dimensional proteomics identifies organ injury patterns associated with outcomes in human trauma. J Trauma Acute Care Surg. 2023. PMID: 36787435. doi:10.1097/TA.0000000000003880

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。